Social Genomic Mechanisms of Health Disparities Among Adolescent and Young Adult (AYA) Survivors of Hodgkin and Non-Hodgkin Lymphoma (EAQ211)

Overview

This study examines the impact of social and genetic factors on outcomes in adolescent and young adult (AYA) cancer survivors of Hodgkin or non-Hodgkin lymphoma. Compared to both older adult and childhood cancer patients, AYAs with cancer experience different diagnoses and specific biological, clinical, psychological and social factors that affect their risks for post-treatment morbidity and premature death. Collecting samples of blood samples and health and treatment information from cancer survivors of Hodgkin or non-Hodgkin lymphoma may help doctors identify conditions that increase the likelihood of AYAs getting sick and dying after treatment of cancer and better understand how to address the needs of adolescent and young adult cancer survivors.

Key Inclusion Criteria

• Patient must be >= 18 years of age at the time of registration

• Patient must have been between the ages of 15-39 at the time of their first primary cancer diagnosis of Hodgkin lymphoma or non-Hodgkin lymphoma (NHL)

• Patient must have completed therapy (with a complete response, per clinician determination) at the time of registration

• Patients last date of prior systemic therapy for first primary diagnosis for Hodgkin lymphoma or non-Hodgkin lymphoma must have been within one year prior to registration

  • NOTE: Systemic therapy refers to all anti-cancer therapy, including but not limited to chemotherapy, intravenous (IV) or oral targeted medications, or radiation, and administered via a clinical trial or standard approach

• Patient must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-3
• Patient must be English speaking in order to be able to complete the required QOL forms on this study

  • NOTE: Sites cannot translate the associated QOL forms

• Patient must not be receiving active therapy for Hodgkin lymphoma or non-Hodgkin lymphoma

• Patient must have internet access through computer, tablet, or smartphone

• Patient must have email address

• Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible

Sponsor(s)

ECOG-ACRIN Cancer Research Group

Learn More

To learn more, visit ClinicalTrials.Gov